CORALLO, DAMIANO SALVATORE
 Distribuzione geografica
Continente #
NA - Nord America 192
AS - Asia 150
EU - Europa 117
OC - Oceania 3
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 465
Nazione #
US - Stati Uniti d'America 186
CN - Cina 84
IT - Italia 61
IE - Irlanda 15
IN - India 15
SG - Singapore 15
JP - Giappone 11
FR - Francia 8
GB - Regno Unito 7
SE - Svezia 7
VN - Vietnam 7
IR - Iran 5
DE - Germania 4
FI - Finlandia 4
NL - Olanda 4
PL - Polonia 4
AU - Australia 3
CA - Canada 3
GT - Guatemala 3
HK - Hong Kong 3
ID - Indonesia 3
KR - Corea 3
BR - Brasile 2
TW - Taiwan 2
AM - Armenia 1
BE - Belgio 1
EU - Europa 1
RU - Federazione Russa 1
TR - Turchia 1
UA - Ucraina 1
Totale 465
Città #
Fairfield 22
Chandler 15
Dublin 15
Santa Clara 15
Woodbridge 13
Singapore 12
Houston 11
Beijing 10
Torino 10
Cambridge 9
Shanghai 9
Guangzhou 8
Seattle 8
Ashburn 7
Dong Ket 7
Mumbai 7
Wilmington 7
San Jose 6
Nanjing 5
Nantong 5
Nyköping 5
Oxford 5
Brugherio 4
Helsinki 4
Pisa 4
Warsaw 4
Columbus 3
Guatemala City 3
Hangzhou 3
Hong Kong 3
Jakarta 3
Jinan 3
Milan 3
New York 3
Ottawa 3
Rajkot 3
Rome 3
San Diego 3
Taishing 3
Tokyo 3
Aioicho 2
Ann Arbor 2
Chagrin Falls 2
Changchun 2
Clermont 2
Kish 2
Lake Forest 2
Lanzhou 2
Leeuwarden 2
Littleton 2
Pontedera 2
Princeton 2
Pune 2
Rivoli 2
Rotterdam 2
Shenyang 2
São Paulo 2
Taipei 2
Tampa 2
Villeurbanne 2
Zhengzhou 2
Aradeo 1
Berlin 1
Bernalda 1
Boston 1
Bovisio Masciago 1
Brisbane 1
Brookline 1
Cairate 1
Coimbatore 1
Dearborn 1
Fukushima 1
Genova 1
Gillingham 1
Hebei 1
Himeji 1
Hounslow 1
Kake 1
Kashan 1
Katy 1
Kochi 1
Köln 1
Leawood 1
Malgrate 1
Medford 1
Merelbeke 1
Minato-ku 1
Newcastle 1
Niigata 1
Ningbo 1
Paris 1
Pleasant Prairie 1
Rochester 1
San Mateo 1
Sandwich 1
Shenzhen 1
Somma Lombardo 1
Tianjin 1
Turin 1
Upper Marlboro 1
Totale 350
Nome #
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 259
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 179
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 37
Totale 475
Categoria #
all - tutte 1.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.116


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202058 0 0 0 0 0 6 9 12 13 7 3 8
2020/202169 5 9 7 6 0 8 6 4 2 7 3 12
2021/202274 8 3 7 10 5 2 2 4 5 3 16 9
2022/202392 5 8 5 4 12 11 5 8 16 3 12 3
2023/202460 10 7 1 4 2 12 2 7 5 2 4 4
2024/202567 3 6 8 11 37 2 0 0 0 0 0 0
Totale 475